Diagnosis: Acute cytomegalovirus (CMV) infection in an immunocompetent host.
This patient was admitted to the hospital, and serologic testing for CMV revealed positive IgM and IgG responses. PCR of a blood sample for CMV DNA revealed 3500 copies/mm 3 . Because of her severe and prolonged symptoms, the patient received oral valgancyclovir (900 mg b.i.d.), with resolution of fever within 24 h after initiation of therapy. At a 2-week followup visit, she noted complete resolution of all of her symptoms, and PCR detected no CMV DNA in a blood sample obtained at that time. The patient received a total of 14 days of therapy without recurrence of disease.
The differential diagnosis of unexplained fever and splenic infarcts in an immunocompetent patient would include embolic events due to endocarditis; viral infections, such as with Epstein-Barr virus and CMV; infectious vasculitis, as observed in neisserial infections; and noninfectious etiologies, including sickle-cell disease, autoimmune vasculitides, and hypercoaguable states [1, 2] .
CMV-related vasculopathy with thrombosis ( figure 1 ) is clinically rare in the immunocompetent host. Jordan et al. [3] reported the first case of a CMV-related splenic infarct in a 26-year-old immunocompetent woman, and Ofotokun et al. [1] described a 50-year-old immunocompetent man with splenic infarcts related to CMV infection. Hepatic and portal vein thrombosis due to CMV infection has also been described in immunocompetent individuals [4] [5] [6] . CMV-associated vasculopathy is more common among immunocompromised patients-in particular, transplant recipients and HIV-infected patients-than among immunocompetent individuals. CMV induces accelerated cardiac allograft vasculopathy in heart transplant recipients [7] , and there is an association between CMV infection and hepatic artery thrombosis in liver transplant recipients [8] . Although CMV infection has long been associated with arterial vasculitis in HIV-infected patients, venous thrombosis has also been documented [9] .
Treatment of acute CMV infection in the immunocompetent host is generally not required unless the disease is considered severe, as characterized by multiorgan involvement. Eddleston et al. [2] reviewed 34 cases of severe CMV infection in immunocompetent patients, 5 of whom received ganciclovir. One of the 5 treated patients died of CNS involvement. The case
